PPAT and xanthinuria type I: In addition, allosteric feedback inhibition by purine nucleotides of phosphoribosyl pyrophosphate amidotransferase, the rate-limiting enzyme in the purine de novo pathway, accounts for the decreased total purine excretion that is observed in patients with XOR deficiency and those taking XOR inhibitors (11, 41).